Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation

K Nissler, D Pohlers, M Hückel, J Simon, R Bräuer, R W Kinne

Methods: C57BL/6 mice with AIA were treated intraperitoneally with the anti-CD4 mAb GK1.5 or control rat IgG on days –1, 0, 1, 3, 5, and 7. Proinflammatory cytokines (IL1β, IL6, and TNFα) were quantified by sandwich ELISA in joint extracts, serum, and supernatants of ex vivo stimulated spleen/lymph node cells or peritoneal macrophages (+LPS/IFNγ). Nitric oxide (NO) levels in supernatants of ex vivo stimulated peritoneal macrophages were measured by the Griess reaction. Proteolytic activity in joint homogenates was analysed by gelatin, casein, and elastin zymography, and substrate assays.

Results: Anti-CD4 treatment significantly reduced joint swelling in acute (days 3, 5) and early chronic AIA (day 7) and diminished inflammation and destruction scores in late chronic AIA (day 21). On day 3, anti-CD4 treatment significantly reduced IL6 levels in all compartments. IL1β was reduced in joint extracts, unaffected in serum or cells from lymphoid organs, and increased in stimulated peritoneal macrophages. TNFα was significantly increased in the joints, decreased in serum, and otherwise unchanged. NO production by stimulated peritoneal macrophages was significantly reduced by anti-CD4 treatment. Lower activity of matrix metalloproteinases and neutrophil elastase was seen in joint extracts of anti-CD4 treated animals than in IgG treated AIA controls.

Conclusion: CD4+ T cell directed treatment had strong local and systemic effects on macrophages. These indirect effects may contribute to the reduction of destructive mediators/joint destruction in AIA.

**METHODS**

**Animals and antibodies**

Female C57BL/6 mice (8–10 weeks of age) were obtained from the Animal Research Facility, Friedrich Schiller University, Jena, Germany. Methylated bovine serum albumin (mBSA), followed by local elicitation through intra-articular injection of mBSA. CD4+ T cells have a central role in experimental arthritis, as shown by successful treatment with mAbs against the T cell receptor, with T cell directed drugs like cyclosporin A, or by T cell transfer of AIA to severe combined immunodeficient (SCID) mice.

However, cells of the monocytic lineage are also crucially involved in the pathogenesis of AIA and RA (reviewed by Kinne et al.). Macrophages appear to have a pivotal role in arthritis because they are numerous in the inflamed synovial membrane and at the cartilage–pannus junction. They show clear signs of activation, such as overexpression of major histocompatibility complex II molecules, proinflammatory or regulatory cytokine growth factors, and matrix metalloproteinases (MMPs). Therefore, macrophages possess broad proinflammatory and destructive abilities, and they contribute considerably to inflammation and joint destruction in acute and chronic phases of arthritides.

Fully activated T cells produce numerous stimulatory signals to monocytes/macrophages—for example, the cytokines interferon γ (IFNγ) and granulocyte macrophage colony stimulating factor, inducing their differentiation or activation, or both. Consequently, anti-CD4 treatment may affect not only T cells but also macrophages, whether indirectly (as in mice, which carry CD4+ macrophages) or directly and indirectly (as in humans, who carry CD4+ macrophages).

Therefore, local and systemic secretion of the proinflammatory macrophage products interleukin (IL)1β, IL6, tumour necrosis factor α (TNFα), and nitric oxide (NO), as well as the local production of tissue degrading enzymes, were investigated during anti-CD4 treatment of acute and early chronic AIA (day –1 to day 7).

**Abbreviations:** AIA, antigen induced arthritis; ELISA, enzyme linked immunosorbent assay; IFNγ, interferon γ; IL, interleukin; LPS, lipopolysaccharide; mAb, monoclonal antibody; mBSA, methylated bovine serum albumin; MMP, matrix metalloproteinase; NE, neutrophil elastase; NO, nitric oxide; PBS, phosphate buffered saline; PHA, polymorphonuclear leucocyte; RA, rheumatoid arthritis; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; TNFα, tumour necrosis factor α.
AIA and anti-CD4 treatment
The animals were immunised on days −21 and −14 by subcutaneous injection of 100 µg mBSA in 50 µl saline, emulsified in 50 µl complete Freund’s adjuvant (Sigma, Deisenhofen, Germany), which was adjusted to 2 mg/ml with heat-killed Mycobacterium tuberculosis (strain H37RA; Difco, Detroit, MI, USA). In addition, the mice received an intraperitoneal injection of 2×10⁹ heat inactivated Bordetella pertussis (Pertussis Reference Centre, Krankenhaus Friedrichshain, Berlin, Germany). Arthritis was elicited on day 0 by injection of 100 µg mBSA in 25 µl saline into the right knee joint cavity, while the left knee joint remained untreated. For anti-CD4 treatment, the mice (n = 10) received 200 µg of the antinouse CD4 mAb GK1.5 on days −1, 0, 1, 3, 5, and 7 of AIA intraperitoneally. Note that the terms “therapy”, “treatment”, and “clinical effects” are used in this study for the sake of presentation, although AIA clearly represents an experimentally induced disorder. The control group (n = 10) was treated with 200 µg rat IgG instead. Joint swelling was measured on days 0, 1, 3, 5, 7, 14, and 21 with an Oditest vernier caliper (Kroepelin Längenmesstechnik, Schlüchtern, Germany) and expressed as the difference (in mm) between the diameter of the right and the left knee joint.

The experimental data are derived from three independent treatment studies, which showed no significant difference for the joint swelling of the two treatment groups.

Histology
Both knee joints were removed on day 3 (acute phase) or on day 21 of AIA (late chronic phase), skinned, and fixed in phosphate buffered formalin. Paraffin sections (5 µm) of EDTA decalcified joints were stained with haematoxylin and eosin. The severity of arthritis was examined by grading the cellular infiltration and joint destruction, as previously described.13

Preparation of joint extracts
Whole knee joints were removed on day 3, snap frozen in liquid N₂, and stored at −70°C. The extracts were obtained by grinding the frozen joints under liquid N₂ with a mortar and a pestle, followed by addition of 2 ml saline and homogenisation with a Dounce homogeniser. After centrifugation for 20 minutes at 1500 g, the supernatant was split into aliquots, and stored at −70°C until further use. Protein concentrations were determined by the BCA assay (Pierce, Rockville, IL, USA) and the measured cytokine levels (in pg) were then normalised to the concentration of total protein (in mg).

Isolation and stimulation of cells
Peritoneal cells were harvested on day 3 by peritoneal lavage with 7 ml ice cold phosphate buffered saline (PBS) containing 5 IU/ml sodium heparin (Liquidem N 25 000; Hoffman-La Roche, Grenzach-Wyhlen, Germany). Cells were washed and resuspended in RPMI 1640, 10% fetal calf serum, 2 mM l-glutamine, 10 mM Hepes (all from Gibco, Karlsruhe, Germany), 100 U/ml penicillin (Jenapharm, Jena, Germany), 100 µg/ml streptomycin (Grüenthal, Stolberg, Germany)—thereafter called R10F². Cells were seeded at 1×10⁶ cells per well in 24 well plates and allowed to adhere for 2 hours at 37°C in a humidified 5% CO₂ atmosphere. After attachment, non-adherent cells were removed by extensive washing with warm RPMI 1640 medium and re-counted to calculate by subtraction the number of adherent cells in the well. The remaining adherent cells normally consist of >95% macrophages.³ For analysis of cytokine and NO production, adherent macrophages were stimulated for 24 hours with lipopolysaccharide (LPS 1 µg/ml; E coli serotype O26:B6; Sigma, Deisenhofen, Germany) and recombinant murine IFNγ (1 ng/ml, R&D Systems, Wiesbaden, Germany).

Single cell suspensions were prepared from lymph nodes and spleens in R10F², seeded at 1×10⁶ cells per well in 24 well plates, and stimulated with LPS/IFNγ as above. Endotoxin contamination of all media and solutions was <1 ng/ml (Limulus Amoebocyte Lysate test; E-Toxate, Sigma). In all cases, cell-free supernatants were harvested after 24 hours, split into aliquots, and stored at −70°C until cytokine analysis.

Figure 1 Joint swelling and histology of AIA. (A) Time course of joint swelling in AIA after treatment with the anti-CD4 mAb GK1.5 or control rat IgG. Results are expressed as means (SEM) of 10 individual animals in each group. Arrows indicate the days of treatment (days −1, 0, 1, 3, 5, and 7). (B) Histological score of joint inflammation and joint destruction in the acute phase (day 3) and the chronic phase (day 21) of AIA. Results are expressed as means (SEM) of 10 individual animals in each group. *p < 0.05, **p < 0.01 in comparison with IgG treated controls.
Cytokine analysis

Concentrations of IL1β, IL6, and TNFα were determined by sandwich enzyme linked immunosorbent assay (ELISA) according to standard procedures using the following antibody pairs: MAB401 and BAF401 (IL1β; R&D Systems); MP5-20F3 and MP5-32C11 (IL6; BD Pharmingen, Heidelberg, Germany); G281-2626 and MP6-XT3 (TNFα; BD Pharmingen).

Determination of NO production

NO production was determined by the Griess reaction, as described previously.18

Immunohistochemistry

Knee joints were removed completely on day 3 of AIA and snap frozen in isopropane/N₂. Cryosections of 6 μm were prepared and air dried. The slides were incubated for 1 hour with primary mAb against the Ly-6G molecule on PMNs (RB6-8C5; BD Pharmingen) or isotype control rat IgG2b mAb. After rinsing, the slides were incubated for 1 hour with secondary goat-antirat IgG conjugated with peroxidase (Dianova, Hamburg, Germany); diaminobenzidine was used as a substrate. The slides were washed and counterstained with haematoxylin. Positively stained cells were scored semiquantitatively by two “blinded” observers (0 = no; 1 = weak; 2 = medium; 3 = strong infiltration of PMNs).

Figure 2 Cytokine levels on day 3 of AIA. Concentrations of IL1β (A, B, C, D, E), IL6 (F, G, H, I, J), and TNFα (K, L, M, N, O) in joint extracts, supernatants of stimulated lymph node cells, spleen cells, or peritoneal macrophages, as well as serum of GK1.5 treated or rat IgG treated mice, as determined by sandwich EUISA. Results are expressed as means (SEM) (n = 6 for each group). *p < 0.05, **p < 0.01 in comparison with IgG treated controls.

Figure 3 Correlations between cytokine levels in joint extracts and joint swelling on day 3 of AIA. Correlations (Spearman rank test) between joint IL1β, IL6, and TNFα levels and joint swelling of individual mice treated with GK1.5 or rat IgG (total of n = 18 for each cytokine).
Determination of proteolytic activity

Joint extracts were first diluted with PBS to a protein content of 1 mg/ml (BCA assay). For zymography, 50 µl of joint extracts from GK1.5 treated (n = 6) or rat IgG treated animals (n = 5) were separated by electrophoresis on a sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE) supplemented with gelatin (0.6 mg/ml), casein (0.5 mg/ml), or elastin (2 mg/ml). After SDS-PAGE, the gels were washed twice with 2.5% Triton X-100 for 30 minutes to remove SDS, once with aqua dest., and finally equilibrated with incubation buffer (100 mM Tris/HCl, 30 mM CaCl₂, 0.05% NaN₃, pH 7.6). The gel was then incubated at 37°C for 20 hours (gelatin, casein) or 72 hours (elastin). For inhibition studies, the incubation buffer was supplemented with MeOSuc-Ala-Ala-Pro-Val-CMK (200 µM; Bachem, Heidelberg, Germany), a specific inhibitor of neutrophil elastase. Staining of protein was performed with Coomassie blue solution (10 ml acetic acid, 40 ml aqua dest., 50 ml methanol, 0.25% Coomassie blue G250) for 40 minutes, de-staining was carried out in methanol/acetic acid/aqua dest. (25/7/68; vol/vol/vol).

For determination of “total” MMP activity, 2 µl of joint extracts were incubated with 5 µM MCA-Pro-Leu-Gly-Leu-DAP(DNP)-Ala-Arg-NH₂ (Bachem) in 100 µl incubation buffer (100 mM Tris/HCl, 30 mM CaCl₂, 0.05% Brij, pH 7.6) for 3 hours at 37°C. Different active MMPs cleave the quenched substrate with varying specific activities, therefore increasing the fluorescence. This was measured in 96 well FLUOTRAC plates (Greiner) using a FLUOstar Galaxy (BMG, Offenburg, Germany; excitation 330 nm, emission 405 nm). The combined activity of active and pro-MMP was determined after activation of pro-MMP with 2 mM amino-ethylmercuric acetate for 15 minutes before substrate determination after activation of pro-MMP with 2 mM amino-ethylmercuric acetate for 15 minutes before substrate determination. 

Statistics

The non-parametric Mann-Whitney U test (two tailed) was applied for analysis of the experimental variables, with significant differences between the anti-CD4 mAb and control IgG group accepted for p ≤ 0.05. The Spearman rank correlation test (r_s) was used to analyse correlations among experimental variables and between these variables and the clinical status of individual mice (p ≤ 0.05). Analyses were performed using the SPSS 10.0 program (SPSS Inc; Chicago, IL, USA).

RESULTS

Clinical effects

Treatment with the depleting anti-CD4 mAb GK1.5 on days −1, 0, 1, 3, 5, and 7 significantly decreased joint swelling already in the acute phase (days 3, 5) and in the early chronic phase of AIA (day 7) compared with rat IgG treated controls (fig 1A).

Decreased disease activity after GK1.5 treatment was confirmed by examination of joint histology. The signs of joint inflammation (as defined by hyperplasia of the synovial lining layer and cellular infiltration) were significantly reduced in GK1.5 treated animals both in acute (day 3) and late chronic AIA (day 21; fig 1B). The joint destruction score, defined as pannus formation and erosion of cartilage and bone, became significantly reduced in late chronic AIA (fig 1B), the phase with maximal joint destruction in untreated AIA.¹⁵

Cytokine levels in local and systemic compartments

Because of the known role of locally and systemically activated macrophages in the AIA model, the levels of major monocyte/macrophage cytokines were evaluated in joint extracts, supernatants of LPS/IFNγ stimulated lymph node cells, spleen cells, and peritoneal macrophages, as well as the serum.

IL1β

In the joints, anti-CD4 treatment significantly decreased IL1β (fig 2A). Whereas anti-CD4 treatment had no effects on stimulated lymph node or spleen cells and in the serum (fig 2B, C, E), a significant increase of IL1β was detected in cultures of LPS/IFNγ stimulated peritoneal macrophages from GK1.5 treated animals (fig 2D). Interestingly, this effect was significantly and negatively correlated with the joint swelling (p = 0.04; r_s = −0.636, n = 12).

IL6

Anti-CD4 treatment significantly reduced levels of IL6 in all compartments investigated—that is, joint extracts, LPS/IFNγ...
stimulated lymph node cells, spleen cells, or peritoneal macrophages, and in the serum (fig 2F–J). In the case of peritoneal macrophages, the effect of anti-CD4 treatment was confirmed at a lower concentration level (IgG treated: 100 pg/ml; anti-CD4 treated: 25 pg/ml; \( p < 0.01 \)) also in non-stimulated cells.

**TNFα**

Treatment with GK1.5 mAbs induced a moderate but significant increase of the TNFα concentration in joint extracts (fig 2K). In contrast, there was a profound and significant decrease of TNFα levels in the serum (fig 2O), whereas LPS/IFNγ stimulated lymph node cells, spleen cells, or peritoneal macrophages were not significantly affected (figs 2L–N).

Significant, positive correlations were detected between the degree of joint swelling in IgG treated or anti-CD4 treated mice and the joint levels of IL1β (\( p = 0.01; r_s = 0.590; n = 18 \)) and IL6 (\( p = 0.03; r_s = 0.517; n = 18 \)) (figs 3A and B), indicating a contribution of these cytokines to joint inflammation. In contrast, a significant negative correlation was seen between joint swelling and the joint levels of TNFα (\( p = 0.01; r_s = -0.581; n = 18 \); fig 3C). Also, positive correlations were found between the IL6 concentrations in all systemic compartments (except for the spleen) and the severity of joint swelling (lymph nodes: \( p = 0.02; r_s = 0.643; n = 12 \); peritoneum: \( p = 0.02; r_s = 0.643; n = 12 \); serum: \( p = 0.003; r_s = 0.629; n = 20 \)).

**NO levels in peritoneal macrophages**

NO levels in supernatants of LPS/IFNγ stimulated peritoneal macrophages from GK1.5 treated animals were significantly reduced in comparison with those from IgG treated mice (fig 4).
Proteolytic activity in joint extracts
MMP and other proteinases are major effector molecules in the destructive process in arthritis. In view of numerically or significantly reduced destruction scores in acute and late chronic AIA after anti-CD4 treatment (fig 1B), the proteolytic activity was investigated in joint extracts derived from acute AIA (day 3). Treatment with GK1.5 significantly reduced the total MMP activity, as measured by cleavage of an MMP-specific, fluorogenic peptide (fig 5). This could not be assigned to changes in MMP-2 or MMP-9 activity, because zymography showed no differences in gelatinolytic activity between anti-CD4 treatment and IgG controls, especially for MMP-2 and MMP-9 (fig 6A). The caseinolytic activity seen at a molecular weight of about 28 kDa was also strongly decreased in GK1.5 treated mice (fig 6B). A comparable difference was noted in the same molecular weight range using elastin as a substrate. By addition of the specific inhibitor MeOSuc-Ala-Ala-Pro-Val-CMK during the incubation, the elastinolytic activity at 28 kDa was unequivocally identified as neutrophil elastase (NE) (fig 6C). The significantly decreased proteolytic activity of NE in joint extracts from GK1.5 treated mice was also confirmed using a chromogenic assay with an NE-specific synthetic substrate (fig 7).

Determination of PMN infiltration
Immunohistological staining of the arthritic joints on day 3 showed that anti-CD4 treatment did not significantly decrease the degree of PMN infiltration (2.6 (0.2) rat IgG; 2.3 (0.3) GK1.5; mean (SEM)), excluding PMN depletion as a reason for the decreased NE activity in joint extracts.

DISCUSSION
Anti-CD4 treatment suppresses joint inflammation and destruction
Treatment with the depleting anti-CD4 mAb GK1.5 during acute and early chronic AIA (days –1 to 7) significantly suppressed joint swelling and histological signs of inflammation in the acute phase of AIA (day 3) and significantly reduced both joint inflammation and destruction in late chronic AIA (day 21). To our knowledge, this is the first evidence that monotherapy with anti-CD4 mAbs not only ameliorates clinical and histological signs of joint inflammation but also prevents/reduces joint destruction in AIA. By comparison, anti-destructive effects have only been seen after treatment of arthritis models either with broadly reactive anti-γβ-T cell receptor antibodies or with combinations of anti-CD4 mAbs and anti-macrophage reagents—that is, anti-TNFα mAbs or liposomes containing clodronate.

Anti-CD4 treatment reduces IL6 both locally and systemically
Anti-CD4 treatment significantly reduced the levels of IL6 in every compartment investigated—that is, joints, lymphoid organs, peritoneum, and serum. IL6 seems to play a clearly proinflammatory part in AIA, as shown by a significant correlation of IL6 levels in synovial fluid and serum with the severity of disease, and by the peak levels of this cytokine in joints, peritoneum, and serum in the acute phase. Our study also showed positive correlations between the severity of joint swelling and the IL6 concentrations in all compartments (except for the spleen; fig 3). Although both pro- and anti-inflammatory properties have been assigned to IL6, this study seems to support a prevalent proinflammatory role of this cytokine. Thus, local and systemic reduction of IL6 by anti-CD4 treatment may contribute to the amelioration of disease activity in AIA, as also reported in human RA and SLE.

Diverging effects of anti-CD4 treatment on local and systemic levels of IL1β
Anti-CD4 treatment significantly reduced local IL1β levels in acute AIA (day 3; fig 2A). This may contribute to the reduced destruction scores at this stage (fig 1B), as supported by a significant, positive correlation between local IL1β levels and joint swelling (fig 3).

In contrast with the high levels of IL1β in the joint (about 1170 pg/ml), this cytokine was found at relatively low systemic levels in the spleen, lymph nodes, serum, and non-stimulated peritoneal macrophages (25–100 pg/ml) in acute AIA, in line with previously published data. This low constitutive expression in untreated AIA and the lack of changes in any systemic compartment (except for peritoneal macrophages) upon anti-CD4 treatment suggest that systemic IL1β may have limited importance in acute AIA.

Unexpectedly, anti-CD4 treatment significantly increased the IL1β release by LPS/IFNγ stimulated peritoneal macrophages ex vivo. This finding suggests the existence of regulatory peritoneal macrophage subpopulations predominantly expressing IL1β, as supported by the following observations: (a) the enhanced IL1β secretion was not seen in any other compartment; (b) the release of the macrophage product NO was diminished by clinically effective anti-CD4 treatment; and (c) there was a significant negative correlation between joint swelling and IL1β production by peritoneal macrophages. Indeed, the FcR positive monocyte subset shows higher expression of IL1β than the FcR negative subset, a population specifically overrepresented in inflammatory conditions like sepsis.

A proinflammatory role for NO
Anti-CD4 treatment decreased NO production by stimulated peritoneal macrophages in parallel with reduction of arthritis in AIA, suggesting a proinflammatory role for NO in the present system. Given that other studies in AIA have reported NO as an anti-inflammatory factor, the net effects of NO on inflammation may depend on the individual tissue and/or organ and cell type. Thus, therapeutic application of iNOS inhibitors should be viewed with particular care (reviewed by Kinne et al).

Possible dual role of TNFα
As in the case of IL1β, anti-CD4 treatment of murine AIA had divergent effects on systemic and local levels of TNFα (reduction in the serum and increase in the joint).
Although TNF\(\alpha\) is usually regarded as a proinflammatory cytokine, in this study the local levels were increased (about 25%) by clinically effective anti-CD4 treatment and negatively correlated with joint swelling (fig 3). Indeed, evidence is growing that TNF\(\alpha\) can also have immunosuppressive effects in some models of autoimmune disease, including arthritis.10 11

In general, the expression of TNF\(\alpha\) in the arthritic joint was relatively low in mouse AIA (about 20-fold lower than IL1\(\beta\) in IgG treated AIA mice), which is similar to the equivalent AIA model in the rat (own unpublished observations). Although TNF\(\alpha\) is a known inducer of proinflammatory cytokines like IL1\(\beta\),12 the anti-CD4-induced increase of local TNF\(\alpha\) was not sufficient to counteract the anti-CD4 induced decrease of IL1\(\beta\). Thus, IL1\(\beta\) may have a more important role than TNF\(\alpha\) in joint inflammation/destruction in arthritis.13 However, it must be considered that small amounts of TNF\(\alpha\) may still be sufficient to promote synovitis.14 15

**Effects of anti-CD4 treatment on proteolytic activity**

Because anti-CD4 treatment inhibited joint destruction in AIA, a possible influence on matrix degrading proteases was also investigated. Indeed, a reduced “total” MMP activity was seen already on day 3. However, the specific MMP target(s) of anti-CD4 treatment remains to be determined because gelatin zymography showed that neither the activity of gelatinase A (MMP-2) nor of gelatinase B (MMP-9) was affected in the acute phase of AIA, and because the activities of MMP-1, -3, or -13 were not visible in cascin zymography.

In addition to the decreased MMP activity, the activity of NE was almost completely blocked. Earlier studies have shown that NE is a major protease of PMNs involved in proteoglycan damage.16 Moreover, NE can activate latent MMP present in the cartilage (for example, MMP-2, -3, and -9), leading to the generation of VDIPEN neoepitopes in the cartilage of animals with immune complex mediated arthritis.17 Consequently, the specific NE inhibitor MeoSucc-Ala-Ala-Pro-Val-CMK completely inhibited proteoglycan depletion in this model.18

IL1\(\beta\) is a known inducer of pro-MMPs,19 which are reduced by anti-CD4 treatment. Also, pro-MMPs require processing by other proteases (such as NE) to become active enzymes. Therefore, reduced local levels of IL1\(\beta\) (resulting in a lower local level of pro-MMPs) and the decreased NE activity in arthritic joints may synergistically contribute to reduced joint destruction after anti-CD4 treatment.

**Indirect influence of anti-CD4 treatment on the functions of CD4\(^+\) macrophages/PMNs**

It is presently unclear how anti-CD4 treatment affects the functions of macrophages or PMNs in AIA. The lack of CD4 expression on these cell populations in the mouse excludes the possibility of direct effects. An indirect influence of CD4\(^+\) T cells on macrophages/PMNs seems probable, because the production of IFN\(\gamma\) is significantly reduced in the spleen and/or lymph node cells after anti-CD4 treatment,20 potentially resulting in counteraction of systemic macrophage activation. Because anti-CD4 treatment did not suppress T cell cytokines in the inflamed joint,21 a local influence of T cell deactivation on macrophage/PMN functions appears unlikely.

Anti-CD4 treatment decreased the NE activity in joint extracts without influencing the density of infiltrating PMNs. This excludes depletion of PMNs or an influence on their trafficking to the inflamed joint—for example by suppressing the production of chemoattractant, T cell derived IL1\(\beta\).22 Rather, decreased NE activity may be mediated by an influence of anti-CD4 mAbs on contact dependent stimulation of PMNs by T cells.23 Such changes in PMN stimulation may reciprocally influence T cell activation—for example, through the suppression of elastin receptors on activated Th or T memory cells24 or through the potential of PMNs to act as accessory cells for T cell activation.25 Because the down regulation of T cell activation by anti-CD4 treatment is restricted to systemic sites,26 this treatment may result in a failure to stimulate the proinflammatory response of monocytes/PMNs before infiltrating the arthritic synovium.

**ACKNOWLEDGEMENTS**

Heidemarie Börner, Uta Griechen, Cornelia Hüttich, Waltraud Kröber, and Renate Stöckigt are gratefully acknowledged for excellent technical assistance, and Dr Ernsta Palombo-Kinne for critical revision of the manuscript.

This work was supported by the Bundesministerium für Bildung und Forschung (grants FKZ 01ZZ9602 and FKZ 01ZZ0105 to RB and RWK) and the Deutsche Forschungsgemeinschaft (grants Br 1372/5 to RB and Ki 439/6–1 and Ki 439/7–1 to RWK).

**Authors’ affiliations**

K Nissler, M Häckel, J Simon, R Bräuer, Institute of Pathology, Friedrich Schiller University, Jena, Germany

D Pohlers, R W Kinne, Experimental Rheumatology Unit, Interdisciplinary Centre of Clinical Research, Friedrich Schiller University, Jena, Germany

Present address of K Nissler: HEUSOS Klinik Borna, Rudolf-Virchow-Str 2, D-04552 Borna, Germany

K Nissler and D Pohlers contributed equally to this work.

**REFERENCES**


Influence of anti-CD4 mAb on macrophage function in AIA


Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation
K Nissler, D Pohlers, M Hückel, J Simon, R Bräuer and R W Kinne

doi: 10.1136/ard.2003.013060

Updated information and services can be found at:
http://ard.bmj.com/content/63/11/1470

These include:

References
This article cites 41 articles, 9 of which you can access for free at:
http://ard.bmj.com/content/63/11/1470#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (5144)
- Degenerative joint disease (4641)
- Inflammation (1251)
- Musculoskeletal syndromes (4951)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/